Wall Street brokerages predict that Brainstorm Cell Therapeutics Inc (NASDAQ:BCLI) will announce ($0.09) earnings per share for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for Brainstorm Cell Therapeutics’ earnings. Brainstorm Cell Therapeutics reported earnings of ($0.03) per share in the same quarter last year, which indicates a negative year over year growth rate of 200%. The company is scheduled to report its next quarterly earnings report on Thursday, March 29th.
According to Zacks, analysts expect that Brainstorm Cell Therapeutics will report full year earnings of ($0.37) per share for the current year. For the next year, analysts expect that the company will report earnings of ($0.42) per share. Zacks Investment Research’s EPS calculations are an average based on a survey of research analysts that cover Brainstorm Cell Therapeutics.
Brainstorm Cell Therapeutics (NASDAQ:BCLI) last issued its quarterly earnings results on Tuesday, October 17th. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.16) by $0.03. During the same period in the prior year, the business earned ($0.09) EPS.
A hedge fund recently raised its stake in Brainstorm Cell Therapeutics stock. Vanguard Group Inc. grew its stake in Brainstorm Cell Therapeutics Inc (NASDAQ:BCLI) by 2.8% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 657,101 shares of the biotechnology company’s stock after acquiring an additional 17,657 shares during the quarter. Vanguard Group Inc. owned about 3.51% of Brainstorm Cell Therapeutics worth $2,733,000 at the end of the most recent quarter. 13.08% of the stock is owned by institutional investors and hedge funds.
Shares of Brainstorm Cell Therapeutics (NASDAQ:BCLI) opened at $3.58 on Friday. Brainstorm Cell Therapeutics has a one year low of $2.48 and a one year high of $5.18. The stock has a market capitalization of $71.04, a P/E ratio of -11.19 and a beta of 2.21.
TRADEMARK VIOLATION NOTICE: This story was first reported by American Banking News and is the property of of American Banking News. If you are viewing this story on another domain, it was illegally copied and reposted in violation of US and international trademark and copyright legislation. The correct version of this story can be accessed at https://www.americanbankingnews.com/2018/01/05/0-09-eps-expected-for-brainstorm-cell-therapeutics-inc-bcli-this-quarter.html.
Brainstorm Cell Therapeutics Company Profile
Brainstorm Cell Therapeutics Inc is a biotechnology company. The Company is engaged in developing adult stem cell therapies for debilitating neurodegenerative disorders, such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig’s disease), Multiple Sclerosis (MS) and Parkinson’s disease (PD), among others.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Brainstorm Cell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Brainstorm Cell Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.